COVID-19 Impact on Ulcerative Colitis Treatment Market, Global Research Reports 2020-2021
Table of Contents1.1 Research Scope
1.2 Market Segmentation
1.3 Research Objectives
1.4 Research Methodology
1.4.1 Research Process
1.4.2 Data Triangulation
1.4.3 Research Approach
1.4.4 Base Year
1.5 Coronavirus Disease 2019 (Covid-19) Impact Will Have a Severe Impact on Global Growth
1.5.1 Covid-19 Impact: Global GDP Growth, 2019, 2020 and 2021 Projections
1.5.2 Covid-19 Impact: Commodity Prices Indices
1.5.3 Covid-19 Impact: Global Major Government Policy
1.6 The Covid-19 Impact on Ulcerative Colitis Treatment Industry
1.7 COVID-19 Impact: Ulcerative Colitis Treatment Market Trends
2 Global Ulcerative Colitis Treatment Quarterly Market Size Analysis
2.1 Ulcerative Colitis Treatment Business Impact Assessment - COVID-19
2.1.1 Global Ulcerative Colitis Treatment Market Size, Pre-COVID-19 and Post- COVID-19 Comparison, 2015-2026
2.2 Global Ulcerative Colitis Treatment Quarterly Market Size 2020-2021
2.3 COVID-19-Driven Market Dynamics and Factor Analysis
2.3.1 Drivers
2.3.2 Restraints
2.3.3 Opportunities
2.3.4 Challenges
3 Quarterly Competitive Assessment, 2020
3.1 By Players, Global Ulcerative Colitis Treatment Quarterly Market Size, 2019 VS 2020
3.2 By Players, Ulcerative Colitis Treatment Headquarters and Area Served
3.3 Date of Key Players Enter into Ulcerative Colitis Treatment Market
3.4 Key Players Ulcerative Colitis Treatment Product Offered
3.5 Mergers & Acquisitions, Expansion Plans
4 Impact of Covid-19 on Ulcerative Colitis Treatment Segments, By Type
4.1 Introduction
1.4.1 Anti-inflammatory Drugs
1.4.2 Immune System Suppressors
1.4.3 Other medications
4.2 By Type, Global Ulcerative Colitis Treatment Market Size, 2019-2021
5 Impact of Covid-19 on Ulcerative Colitis Treatment Segments, By Application
5.1 Overview
5.5.1 Hospital
5.5.2 Clinic
5.5.3 Drugs Store
5.5.4 Others
5.2 By Application, Global Ulcerative Colitis Treatment Market Size, 2019-2021
5.2.1 By Application, Global Ulcerative Colitis Treatment Market Size by Application, 2019-2021
6 Geographic Analysis
6.1 Introduction
6.2 North America
6.2.1 Macroeconomic Indicators of US
6.2.2 US
6.2.3 Canada
6.3 Europe
6.3.1 Macroeconomic Indicators of Europe
6.3.2 Germany
6.3.3 France
6.3.4 UK
6.3.5 Italy
6.4 Asia-Pacific
6.4.1 Macroeconomic Indicators of Asia-Pacific
6.4.2 China
6.4.3 Japan
6.4.4 South Korea
6.4.5 India
6.4.6 ASEAN
6.5 Rest of World
6.5.1 Latin America
6.5.2 Middle East and Africa
7 Company Profiles
7.1 Pfizer
7.1.1 Pfizer Business Overview
7.1.2 Pfizer Ulcerative Colitis Treatment Quarterly Revenue, 2020
7.1.3 Pfizer Ulcerative Colitis Treatment Product Introduction
7.1.4 Pfizer Response to COVID-19 and Related Developments
7.2 Novartis
7.2.1 Novartis Business Overview
7.2.2 Novartis Ulcerative Colitis Treatment Quarterly Revenue, 2020
7.2.3 Novartis Ulcerative Colitis Treatment Product Introduction
7.2.4 Novartis Response to COVID-19 and Related Developments
7.3 Roche
7.3.1 Roche Business Overview
7.3.2 Roche Ulcerative Colitis Treatment Quarterly Revenue, 2020
7.3.3 Roche Ulcerative Colitis Treatment Product Introduction
7.3.4 Roche Response to COVID-19 and Related Developments
7.4 Sanofi
7.4.1 Sanofi Business Overview
7.4.2 Sanofi Ulcerative Colitis Treatment Quarterly Revenue, 2020
7.4.3 Sanofi Ulcerative Colitis Treatment Product Introduction
7.4.4 Sanofi Response to COVID-19 and Related Developments
7.5 GSK
7.5.1 GSK Business Overview
7.5.2 GSK Ulcerative Colitis Treatment Quarterly Revenue, 2020
7.5.3 GSK Ulcerative Colitis Treatment Product Introduction
7.5.4 GSK Response to COVID-19 and Related Developments
7.6 AstraZeneca
7.6.1 AstraZeneca Business Overview
7.6.2 AstraZeneca Ulcerative Colitis Treatment Quarterly Revenue, 2020
7.6.3 AstraZeneca Ulcerative Colitis Treatment Product Introduction
7.6.4 AstraZeneca Response to COVID-19 and Related Developments
7.7 MSD
7.7.1 MSD Business Overview
7.7.2 MSD Ulcerative Colitis Treatment Quarterly Revenue, 2020
7.7.3 MSD Ulcerative Colitis Treatment Product Introduction
7.7.4 MSD Response to COVID-19 and Related Developments
7.8 Johnson & Johnson
7.8.1 Johnson & Johnson Business Overview
7.8.2 Johnson & Johnson Ulcerative Colitis Treatment Quarterly Revenue, 2020
7.8.3 Johnson & Johnson Ulcerative Colitis Treatment Product Introduction
7.8.4 Johnson & Johnson Response to COVID-19 and Related Developments
7.9 Bayer
7.9.1 Bayer Business Overview
7.9.2 Bayer Ulcerative Colitis Treatment Quarterly Revenue, 2020
7.9.3 Bayer Ulcerative Colitis Treatment Product Introduction
7.9.4 Bayer Response to COVID-19 and Related Developments
7.10 AbbVie
7.10.1 AbbVie Business Overview
7.10.2 AbbVie Ulcerative Colitis Treatment Quarterly Revenue, 2020
7.10.3 AbbVie Ulcerative Colitis Treatment Product Introduction
7.10.4 AbbVie Response to COVID-19 and Related Developments
7.11 Eli Lilly and Company
7.11.1 Eli Lilly and Company Business Overview
7.11.2 Eli Lilly and Company Ulcerative Colitis Treatment Quarterly Revenue, 2020
7.11.3 Eli Lilly and Company Ulcerative Colitis Treatment Product Introduction
7.11.4 Eli Lilly and Company Response to COVID-19 and Related Developments
7.12 Amgen
7.12.1 Amgen Business Overview
7.12.2 Amgen Ulcerative Colitis Treatment Quarterly Revenue, 2020
7.12.3 Amgen Ulcerative Colitis Treatment Product Introduction
7.12.4 Amgen Response to COVID-19 and Related Developments
7.13 Takeda Pharmaceuticals Company
7.13.1 Takeda Pharmaceuticals Company Business Overview
7.13.2 Takeda Pharmaceuticals Company Ulcerative Colitis Treatment Quarterly Revenue, 2020
7.13.3 Takeda Pharmaceuticals Company Ulcerative Colitis Treatment Product Introduction
7.13.4 Takeda Pharmaceuticals Company Response to COVID-19 and Related Developments
7.14 Ferring Pharmaceuticals
7.14.1 Ferring Pharmaceuticals Business Overview
7.14.2 Ferring Pharmaceuticals Ulcerative Colitis Treatment Quarterly Revenue, 2020
7.14.3 Ferring Pharmaceuticals Ulcerative Colitis Treatment Product Introduction
7.14.4 Ferring Pharmaceuticals Response to COVID-19 and Related Developments
7.15 InDeX Pharmaceuticals
7.15.1 InDeX Pharmaceuticals Business Overview
7.15.2 InDeX Pharmaceuticals Ulcerative Colitis Treatment Quarterly Revenue, 2020
7.15.3 InDeX Pharmaceuticals Ulcerative Colitis Treatment Product Introduction
7.15.4 InDeX Pharmaceuticals Response to COVID-19 and Related Developments
8 Key Findings
9 Appendix
9.1 About US
9.2 Disclaimer
List of TablesTable 1. Overview of the World Economic Outlook Projections
Table 2. Summary of World Real per Capita Output (Annual percent change; in international currency at purchasing power parity)
Table 3. European Economies: Real GDP, Consumer Prices, Current Account Balance, and Unemployment (Annual percent change, unless noted otherwise)
Table 4. Asian and Pacific Economies: Real GDP, Consumer Prices, Current Account Balance, and Unemployment (Annual percent change, unless noted otherwise)
Table 5. Western Hemisphere Economies: Real GDP, Consumer Prices, Current Account Balance, and Unemployment (Annual percent change, unless noted otherwise)
Table 6. Middle Eastern and Central Asian Economies: Real GDP, Consumer Prices, Current Account Balance, and Unemployment (Annual percent change, unless noted otherwise)
Table 7. Covid-19 Impact: Global Major Government Policy
Table 8. The Covid-19 Impact on Ulcerative Colitis Treatment Assessment
Table 9. COVID-19 Impact: Ulcerative Colitis Treatment Market Trends
Table 10. COVID-19 Impact Global Ulcerative Colitis Treatment Market Size
Table 11. Global Ulcerative Colitis Treatment Quarterly Market Size, 2020 (US$ Million)
Table 12. Global Ulcerative Colitis Treatment Market Size, Pre-COVID-19 and Post- COVID-19 Quarterly Comparison, 2020-2021 (US$ Million)
Table 13. Global Ulcerative Colitis Treatment Market Growth Drivers
Table 14. Global Ulcerative Colitis Treatment Market Restraints
Table 15. Global Ulcerative Colitis Treatment Market Opportunities
Table 16. Global Ulcerative Colitis Treatment Market Challenges
Table 17. By Players, Ulcerative Colitis Treatment Quarterly Revenue, 2019 VS 2020 (US$ Million)
Table 18. Key Players, Ulcerative Colitis Treatment Revenue Market Share, 2019 VS 2020 (%)
Table 19. Key Ulcerative Colitis Treatment Players Headquarters and Area Served
Table 20. Date of Key Players Enter into Ulcerative Colitis Treatment Market
Table 21. Key Players Ulcerative Colitis Treatment Product Type
Table 22. Mergers & Acquisitions, Expansion Plans
Table 23. By Players, Global Ulcerative Colitis Treatment Market Size 2019-2021, (US$ Million)
Table 24. Global Ulcerative Colitis Treatment Market Size by Application: 2019-2021 (US$ Million)
Table 25. Global Ulcerative Colitis Treatment Market Size by Region, 2019-2021 (US$ Million)
Table 26. By Country, North America Ulcerative Colitis Treatment Market Size, 2019-2021 (US$ Million)
Table 27. By Type, US Ulcerative Colitis Treatment Market Size, 2019-2021 (US$ Million)
Table 28. By Application, US Ulcerative Colitis Treatment Market Size, 2019-2021 (US$ Million)
Table 29. By Type, Canada Ulcerative Colitis Treatment Market Size, 2019-2021 (US$ Million)
Table 30. By Application, Canada Ulcerative Colitis Treatment Market Size, 2019-2021 (US$ Million)
Table 31. Macroeconomic Indicators of Europe (Germany, France, UK and Italy)
Table 32. By Country, Europe Ulcerative Colitis Treatment Market Size, 2019-2021 (US$ Million)
Table 33. By Type, Germany Ulcerative Colitis Treatment Market Size, 2019-2021 (US$ Million)
Table 34. By Application, Germany Ulcerative Colitis Treatment Market Size, 2019-2021 (US$ Million)
Table 35. By Type, France Ulcerative Colitis Treatment Market Size, 2019-2021 (US$ Million)
Table 36. By Application, France Ulcerative Colitis Treatment Market Size, 2019-2021 (US$ Million)
Table 37. By Type, UK Ulcerative Colitis Treatment Market Size, 2019-2021 (US$ Million)
Table 38. By Application, UK Ulcerative Colitis Treatment Market Size, 2019-2021 (US$ Million)
Table 39. By Type, Italy Ulcerative Colitis Treatment Market Size, 2019-2021 (US$ Million)
Table 40. By Application, Italy Ulcerative Colitis Treatment Market Size, 2019-2021 (US$ Million)
Table 41. Macroeconomic Indicators of Asia-Pacific (China, Japan, South Korea, India and ASEAN)
Table 42. By Region, Asia-Pacific Ulcerative Colitis Treatment Market Size, 2019-2021 (US$ Million)
Table 43. By Type, China Ulcerative Colitis Treatment Market Size, 2019-2021 (US$ Million)
Table 44. By Application, China Ulcerative Colitis Treatment Market Size, 2019-2021 (US$ Million)
Table 45. By Type, Japan Ulcerative Colitis Treatment Market Size, 2019-2021 (US$ Million)
Table 46. By Application, Japan Ulcerative Colitis Treatment Market Size, 2019-2021 (US$ Million)
Table 47. By Type, South Korea Ulcerative Colitis Treatment Market Size, 2019-2021 (US$ Million)
Table 48. By Application, South Korea Ulcerative Colitis Treatment Market Size, 2019-2021 (US$ Million)
Table 49. By Type, India Ulcerative Colitis Treatment Market Size, 2019-2021 (US$ Million)
Table 50. By Application, India Ulcerative Colitis Treatment Market Size, 2019-2021 (US$ Million)
Table 51. By Type, ASEAN Ulcerative Colitis Treatment Market Size, 2019-2021 (US$ Million)
Table 52. By Application, ASEAN Ulcerative Colitis Treatment Market Size, 2019-2021 (US$ Million)
Table 53. By Type, Latin America Ulcerative Colitis Treatment Market Size, 2019-2021 (US$ Million)
Table 54. By Application, Latin America Ulcerative Colitis Treatment Market Size, 2019-2021 (US$ Million)
Table 55. By Type, Middle East and Africa Ulcerative Colitis Treatment Market Size, 2019-2021 (US$ Million)
Table 56. By Application, Middle East and Africa Ulcerative Colitis Treatment Market Size, 2019-2021 (US$ Million)
Table 57. Pfizer Business Overview
Table 58. Pfizer Ulcerative Colitis Treatment Revenue (US$ Million), (Q1, Q2, Q3, Q4) Quarter 2020
Table 59. Pfizer Ulcerative Colitis Treatment Product
Table 60. Pfizer Response to COVID-19 and Related Developments
Table 61. Novartis Business Overview
Table 62. Novartis Ulcerative Colitis Treatment Revenue (US$ Million), (Q1, Q2, Q3, Q4) Quarter 2020
Table 63. Novartis Ulcerative Colitis Treatment Product
Table 64. Novartis Response to COVID-19 and Related Developments
Table 65. Roche Business Overview
Table 66. Roche Ulcerative Colitis Treatment Revenue (US$ Million), (Q1, Q2, Q3, Q4) Quarter 2020
Table 67. Roche Ulcerative Colitis Treatment Product
Table 68. Roche Response to COVID-19 and Related Developments
Table 69. Sanofi Business Overview
Table 70. Sanofi Ulcerative Colitis Treatment Revenue (US$ Million), (Q1, Q2, Q3, Q4) Quarter 2020
Table 71. Sanofi Ulcerative Colitis Treatment Product
Table 72. Sanofi Response to COVID-19 and Related Developments
Table 73. GSK Business Overview
Table 74. GSK Ulcerative Colitis Treatment Revenue (US$ Million), (Q1, Q2, Q3, Q4) Quarter 2020
Table 75. GSK Ulcerative Colitis Treatment Product
Table 76. GSK Response to COVID-19 and Related Developments
Table 77. AstraZeneca Business Overview
Table 78. AstraZeneca Ulcerative Colitis Treatment Revenue (US$ Million), (Q1, Q2, Q3, Q4) Quarter 2020
Table 79. AstraZeneca Ulcerative Colitis Treatment Product
Table 80. AstraZeneca Response to COVID-19 and Related Developments
Table 81. MSD Business Overview
Table 82. MSD Ulcerative Colitis Treatment Revenue (US$ Million), (Q1, Q2, Q3, Q4) Quarter 2020
Table 83. MSD Ulcerative Colitis Treatment Product
Table 84. MSD Response to COVID-19 and Related Developments
Table 85. Johnson & Johnson Business Overview
Table 86. Johnson & Johnson Ulcerative Colitis Treatment Revenue (US$ Million), (Q1, Q2, Q3, Q4) Quarter 2020
Table 87. Johnson & Johnson Ulcerative Colitis Treatment Product
Table 88. Johnson & Johnson Response to COVID-19 and Related Developments
Table 89. Bayer Business Overview
Table 90. Bayer Ulcerative Colitis Treatment Revenue (US$ Million), (Q1, Q2, Q3, Q4) Quarter 2020
Table 91. Bayer Ulcerative Colitis Treatment Product
Table 92. Bayer Response to COVID-19 and Related Developments
Table 93. AbbVie Business Overview
Table 94. AbbVie Ulcerative Colitis Treatment Revenue (US$ Million), (Q1, Q2, Q3, Q4) Quarter 2020
Table 95. AbbVie Ulcerative Colitis Treatment Product
Table 96. AbbVie Response to COVID-19 and Related Developments
Table 97. Eli Lilly and Company Business Overview
Table 98. Eli Lilly and Company Ulcerative Colitis Treatment Revenue (US$ Million), (Q1, Q2, Q3, Q4) Quarter 2020
Table 99. Eli Lilly and Company Ulcerative Colitis Treatment Product
Table 100. Eli Lilly and Company Response to COVID-19 and Related Developments
Table 101. Amgen Business Overview
Table 102. Amgen Ulcerative Colitis Treatment Revenue (US$ Million), (Q1, Q2, Q3, Q4) Quarter 2020
Table 103. Amgen Ulcerative Colitis Treatment Product
Table 104. Amgen Response to COVID-19 and Related Developments
Table 105. Takeda Pharmaceuticals Company Business Overview
Table 106. Takeda Pharmaceuticals Company Ulcerative Colitis Treatment Revenue (US$ Million), (Q1, Q2, Q3, Q4) Quarter 2020
Table 107. Takeda Pharmaceuticals Company Ulcerative Colitis Treatment Product
Table 108. Takeda Pharmaceuticals Company Response to COVID-19 and Related Developments
Table 109. Ferring Pharmaceuticals Business Overview
Table 110. Ferring Pharmaceuticals Ulcerative Colitis Treatment Revenue (US$ Million), (Q1, Q2, Q3, Q4) Quarter 2020
Table 111. Ferring Pharmaceuticals Ulcerative Colitis Treatment Product
Table 112. Ferring Pharmaceuticals Response to COVID-19 and Related Developments
Table 113. InDeX Pharmaceuticals Business Overview
Table 114. InDeX Pharmaceuticals Ulcerative Colitis Treatment Revenue (US$ Million), (Q1, Q2, Q3, Q4) Quarter 2020
Table 115. InDeX Pharmaceuticals Ulcerative Colitis Treatment Product
Table 116. InDeX Pharmaceuticals Response to COVID-19 and Related Developments
List of FiguresFigure 1. Ulcerative Colitis Treatment Product Picture
Figure 2. Ulcerative Colitis Treatment Market Segmentation
Figure 3. Research Objectives
Figure 4. Research Process
Figure 5. Data Triangulation
Figure 6. Research Approach
Figure 7. Commodity Prices-Metals Price Indices
Figure 8. Commodity Prices- Precious Metal Price Indices
Figure 9. Commodity Prices- Agricultural Raw Material Price Indices
Figure 10. Commodity Prices- Food and Beverage Price Indices
Figure 11. Commodity Prices- Fertilizer Price Indices
Figure 12. Commodity Prices- Energy Price Indices
Figure 13. G20+: Economic Policy Responses to COVID-19
Figure 14. Global Ulcerative Colitis Treatment Market Size, Pre-COVID-19 and Post- COVID-19 Comparison, 2015-2026 (US$ Million)
Figure 15. Global Ulcerative Colitis Treatment Market Size, Pre-COVID-19 and Post- COVID-19, Year-over-Year Growth Rate, 2015-2026 (%)
Figure 16. Global Ulcerative Colitis Treatment Market Size, Quarterly Growth, 2020-2021 (%)
Figure 17. Global Ulcerative Colitis Treatment Market Size, Market Share by Type, 2019 VS 2020 (%)
Figure 18. Global Ulcerative Colitis Treatment Market Size, Market Share by Application, 2019 VS 2020 (%)
Figure 19. Global Ulcerative Colitis Treatment Market Size Market Share by Region, 2019 VS 2020 (%)
Figure 20. United States Composite PMI and GDP
Figure 21. Eurozone Composite PMI and GDP
Figure 22. Eurozone Core v. Periphery PMI Output Indices
Figure 23. Core v. Periphery PMI Employment Indices
Figure 24. UK Composite PMI and GDP
Figure 25. Caixin China Composite Output Index
Figure 26. Caixin China General Services Business Activity Index
Figure 27. Japan Composite Output Index
Figure 28. South Korea Manufacturing PMI
Figure 29. India Composite Output Index
Figure 30. ASEAN Manufacturing PMI
Figure 31. By Region, Asia-Pacific Ulcerative Colitis Treatment Market Size Market Share, 2019-2021